Aurinia Pharmaceuticals (AUPH) Other financing activities (2020 - 2026)

Aurinia Pharmaceuticals' Other financing activities history runs 7 years deep, the most recent figure standing at $713000.0 for Q1 2026.

• Quarterly Other financing activities fell 92.32% year-over-year to $713000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (down 53.01% YoY) and the FY2025 annual result came in at $14.2 million, up 73.34% from the prior year.
• Other financing activities was $713000.0 for Q1 2026 at Aurinia Pharmaceuticals, down from $1.6 million in the prior quarter.
• Across five years, Other financing activities topped out at $9.3 million in Q1 2025 and bottomed at -$184000.0 in Q4 2022.
• A 5-year average of $1.9 million and a median of $1.3 million in 2022 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities sank 102.04% — and 2023, when it soared 858.15%.
• Aurinia Pharmaceuticals' Other financing activities stood at -$184000.0 in 2022, then surged by 858.15% to $1.4 million in 2023, then gained by 18.21% to $1.6 million in 2024, then declined by 2.55% to $1.6 million in 2025, then plunged by 55.63% to $713000.0 in 2026.
• Business Quant data shows AUPH's Other financing activities at $713000.0 in Q1 2026, $1.6 million in Q4 2025, and $2.0 million in Q3 2025.